The cancer-immune dialogue in the context of stress

Although there is little direct evidence supporting that stress affects cancer incidence, it does influence the evolution, dissemination and therapeutic outcomes of neoplasia, as shown in human epidemiological analyses and mouse models. The experience of and response to physiological and psychological stressors can trigger neurological and endocrine alterations, which subsequently influence malignant (stem) cells, stromal cells and immune cells in the tumour microenvironment, as well as systemic factors in the tumour macroenvironment. Importantly, stress-induced neuroendocrine changes that can regulate immune responses have been gradually uncovered. Numerous stress-associated immunomodulatory molecules (SAIMs) can reshape natural or therapy-induced antitumour responses by engaging their corresponding receptors on immune cells. Moreover, stress can cause systemic or local metabolic reprogramming and change the composition of the gastrointestinal microbiota which can indirectly modulate antitumour immunity. Here, we explore the complex circuitries that link stress to perturbations in the cancer-immune dialogue and their implications for therapeutic approaches to cancer. Epidemiological studies and mouse models suggest that stress can affect the evolution, dissemination and outcome of malignancies. In this Review, Ma and Kroemer present insights into the complex neuro-immune interactions that link stress to cancer, with a focus on stress-associated immunomodulatory molecules, and discuss their implications for cancer therapy.

Automated summary

While there is little direct evidence supporting the effect of stress on cancer incidence, it does impact the evolution, dissemination, and therapeutic outcomes of tumors. Neuroendocrine changes and stress-associated immunomodulatory molecules play important roles in the interaction between stress and cancer immunity, with implications for cancer therapy.